Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Epstein-Barr virus nuclear antigen (EBNA) preparations from three sources were tested with sera from normal individuals and patients with Hodgkin's disease, breast carcinoma, Burkitt's lymphoma, and American and Chinese nasopharyngeal carcinoma. Individual sera with discordant antibody patterns were noted in all groups. Sera from both NPC groups gave significantly higher anti-EBNA titers on cell lines converted with P3HR-1 or B95-8 virus compared with anti-EBNA titers on Raji cells. Anti-EBNA titers of Chinese NPC sera showed no correlation among the three EBNA sources, while all other groups had highly correlated titers. Cross-absorption experiments present evidence for more than one antigenic determinant on EBNA. These results suggest an additional parameter for distinguishing Chinese NPC from other EBV-related disorders.
 ...
PMID:Discordant Epstein-Barr virus nuclear antigen (EBNA) antibody patterns in nasopharyngeal carcinoma. 629 66

An EBV variant has been identified in NPC tissues in Taiwan. This EBV variant contains a point mutation in exon I of the LMP I gene. This mutation results in the loss of an XhoI site at nt 169,426, which is present in strain B95-8. In addition, this variant contains a 30-bp deletion in exon 3 of the gene. The recent demonstration of the prevalence of EBV-containing nasal and peripheral T-cell lymphoma in this region drove us to evaluate the presence of this NPC-EBV strain in 7 cases of T-cell lymphoma, as well as in 48 NPC tissues, 2 cases of Hodgkin's disease and I B-cell lymphoma. Four samples of normal lymph node tissue, 40 of normal nasopharynx tissue and 78 throat washings of healthy individuals were included for comparison. We used sequence-specific primers and the polymerase chain reaction (PCR) method to amplify LMP I gene fragments containing these variations. Mutations were then confirmed by restriction-enzyme digestion and the DNA sequencing analysis. Our results showed that 57 of 58 tumor-tissues samples were EBV-positive. Among them, 56, including 6 T-cell-lymphoma samples, belonged to the NPC strain. This strain of EBV was also present in 92% of EBV-positive normal nasopharynx tissues and in 84% of EBV-positive throat washings of the healthy individuals tested. These results suggest that the NPC-EBV strain is prominently present in Taiwan.
 ...
PMID:Detection of an Epstein-Barr-virus variant in T-cell-lymphoma tissues identical to the distinct strain observed in nasopharyngeal carcinoma in the Taiwanese population. 755 13

Antibodies to the Epstein-Barr virus (EBV)-encoded membrane proteins, LMP2A and LMP2B, were assayed in 540 individuals, including 154 patients with nasopharyngeal carcinoma, 16 with African Burkitt's lymphoma, 113 with Hodgkin's disease, 14 with EBV-carrying gastric carcinoma, 14 with oral hairy leucoplakia (HIV+ patients), 37 with non-Hodgkin's lymphoma, 49 with tumours of the head/neck, 19 with infectious mononucleosis, 62 with chronic illnesses with EBV titres consistent with re-activations, and 62 healthy controls. A novel assay, mouse monoclonal enhanced indirect immunofluorescence assay (MIFA) was designed and used to test the sera for antibodies to the LMP2A and 2B proteins, expressed in human keratinocytes. Antibody to both LMP2A and LMP2B was strikingly specific to NPC. Virtually all (99 of 101) of the LMP2 antibody positive individuals were NPC patients, 95% of whom had antibodies that reacted both with the LMP2A- and LMP2B-transfected indicator cells, while the remaining 5% reacted only with the LMP2B expressing cells.
 ...
PMID:Antibodies to LMP2A/2B in EBV-carrying malignancies. 854 Nov 16

To evaluate applications of highly purified recombinant EBV DNAase in the diagnosis and prognosis of NPC, we tested sera from patients with NPC, other EBV-associated diseases and EBV-seropositive and -seronegative healthy subjects by immunoblotting and DNAase inhibitory assay. The results were compared with those obtained by the conventional immunofluorescence assays against the EBV-specified early antigens and capsid antigens. The antigenic specificity of the immunoblotting assay for IgG antibody against the viral enzyme, but not that for the IgA antibody, was correlated with DNAase-inhibitory activity of the sera and their titers of IgG antibodies against the viral early antigens. Purified IgA as well as IgG from NPC sera inhibited enzyme activity with similar efficiency. The use of highly purified viral DNase has increased the sensitivity of detection of the corresponding antibodies by immunoblotting, with the IgG antibody being detected in all but one, and IgA antibody in all but 2, of the 174 NPC sera tested. The IgG antibody was also commonly detected in the other groups of control sera, while the IgA antibody was detected in about 10% of African Burkitt's lymphoma and Algerian Hodgkin's lymphoma patients and less than 3% of the other control subjects. These results suggest that IgA antibody against recombinant EBV DNAase may be useful in the diagnosis of NPC, but the level of this antibody did not appear to be related to clinical stages of this cancer.
 ...
PMID:Purified recombinant EBV desoxyribonuclease in serological diagnosis of nasopharyngeal carcinoma. 862 Dec 54

In a previous study of Epstein-Barr virus (EBV) strains in North African nasopharyngeal carcinoma (N PC) biopsies, we have found that the viral strain present was of A/F/W'-I'/Xhol kept/H1-H2 type, while the strain associated with Chinese NPC was the A/"f"/W'I'/Xhol lost/H type. Using the restriction fragment length polymorphism (RFLP) and PCR-RFLP methods, the present study analyzed the H1-H2 variant in different clinical samples from Algeria, including the saliva of healthy EBV-positive individuals and patients with NPC or Hodgkin's disease (HD), as well as HD biopsies and lymphoblastoid cell lines (LCLs) established from the oropharyngeal virus-infected cells. Our results demonstrate that, in contrast to the H1-H2 variant found in NPC biopsies, the H genotype was dominant in HD biopsies. Moreover, H genotype was also dominant in the oropharynx of healthy EBV-positive individuals, of patients with NPC and with HD. Our results clearly indicate that in North Africa the EBV strain present of NPC biopsies is different from that shed in the oropharynx. This may suggest a specific distribution of the H1-H2 variant in the NPC epithelial tumor, whereas the H genotype is dominant in HD biopsies and in the oropharynx. The specific association of both viral strains with these 2 distinct diseases in North Africa may reflect a difference in tumorigenicity.
 ...
PMID:Different distribution of H1-H2 Epstein-Barr virus variant in oropharyngeal virus and in biopsies of Hodgkin's disease and in nasopharyngeal carcinoma from Algeria. 965 May 53

Epstein-Barr virus (EBV), a gamma herpesvirus, has been associated with a variety of human malignancies such as Burkitt's lymphoma, Hodgkin's lymphoma, NPC, and gastric cancer. A controversy regarding the association of EBV with breast cancers has recently been reported in the literature. These reports have mainly used the DNA detection techniques of polymerase chain reaction and Southern blot hybridization, with the inherent lacunae associated with these techniques for signal localization. Our group has studied EBV association with breast cancer by using in situ hybridization for detecting nonpolyadenylated EBV RNA (EBERs), along with using protein localization technique of immunohistochemistry, studying the EBV nuclear antigen 1 (EBNA1) and the latent membrane proteins (LMP1 and LMP2A). This is the first article analyzing the expression of LMP2A in breast cancer cells. In all of our 43 female breast cancer cases under study, we failed to detect expression of any of the EBV viral gene products tested.
 ...
PMID:Lack of expression of the Epstein-Barr Virus (EBV) gene products, EBERs, EBNA1, LMP1, and LMP2A, in breast cancer cells. 1221 80

Cancer incidence data collected by the Guam Cancer Registry for the period 1998 through 2002 were analyzed by cancer site, age, and ethnicity. Ethnicity and site specific age-adjusted cancer incidence rates for Guam residents were calculated utilizing Guam 2000 census data and the U.S. 2000 standard population and were compared to U.S. 2000 data. Age-adjusted total cancer incidence rates per 100,000 population for the major ethnic groups represented on Guam were generally lower than U.S. averages (the exception was the Caucasian group which was higher). Some highlights include: 1). Chamorros (the indigenous people of the Mariana Islands) living on Guam had a slightly lower total cancer incidence rate than the total U.S. population (406.8/100,000 vs. 478.6 U.S.). Chamorros had high age-adjusted incidence rates for cancers of the mouth and pharynx (24.4 vs. U.S. 10.7), nasopharynx (13.9 vs. 0.6 U.S.), liver (13.2 vs. 5.2 U.S.), and cervix (16.2 vs. 9.6 U.S.). Rates for prostate cancer ( 103.9 vs. 167.7 U.S.), female breast (115.9 vs. 130.9 U.S.), ovary (7.0 vs. 14.2 U.S.), colon-rectum-anus (44.3 vs. 56.9 U.S.), leukemia (11.0 vs. 12.6 U.S.), and non-Hodgkin lymphoma (7.0 vs. 18.9 U.S.) were all lower than U.S. rates. 2). Filipinos living on Guam had high age-adjusted incidence rates for cancers of the nasopharynx (5.1), and liver (9.6). Filipinos had low age-adjusted incidence rates for all cancers (215.7), cancers of the mouth and pharynx when NPC was excluded (4.8), lung and bronchus (35.6 vs. U.S. 70.1), pancreas (1.7 vs. U.S. 11.1), colon-rectum-anus (37.1), female breast (60.7), prostate (46.1), leukemia (4.7), and non-Hodgkin lymphoma (8.4). 3). Micronesians other than Chamorros had the highest age-adjusted incidence rates for cancers of the lung and bronchus (111.5), liver (39.4), and cervix (27.4). Micronesians had low age-adjusted incidence rates for cancers of the colon-rectum-anus (4.1), female breast (35.0), prostate (78.4), leukemia (6.3), and non-Hodgkin lymphoma (6.6). 4). Asians had low total age-adjusted cancer incidence rates (149.7) but had high nasopharyngeal cancer (5.4) and liver (10.7) cancer rates. Asians had low rates of cancers of the mouth and pharynx when nasopharyngeal cancers were excluded (1.4), lung and bronchus cancers (25.8), colon-rectum-anus (26.3), female breast (63.0), ovary (no cases recorded), prostate (31.3), leukemia (5.0) and non-Hodgkin lymphoma (4.9). 5).Caucasians residing on Guam had high age-adjusted cancer incidence rates for cancers of the colon-rectum-anus (91.4), female breast (148.6), ovary (34.7), and leukemia (17.7). Caucasians had low age-adjusted cancer incidence rates for nasopharyngeal cancer (no cases recorded), liver (4.0) and non-Hodgkin lymphoma (7.9). Suggestions are made for further research to explain the ethnic disparitiesin cancer incidence observed on Guam and to develop strategies for ameliorating these disparities.
 ...
PMID:Ethnic disparities in cancer incidence among residents of Guam. 1946 25

It has been shown that the T-regulatory cells (Tregs) not only play a key role in the establishment and maintenance of peripheral tolerance to prevent the autoimmune disease, but also inhibit the anti-tumor immunity. Recently, many studies have demonstrated that cytotoxicity T cells (CTL) can control the growth of EBV-positive tumor cells in vitro, including Hodgkin's lymphoma (HL), nasopharyngeal carcinoma, posttransplantation lymphoproliferative disorders (PTLD), depending on the large mount of EBV antigens presented by MHC molecules on the surface of these malignant cells. However, limited benefit of CTL adoptive immunotherapy has been reported in the treatment of EBV positive HL and NPC, and Tregs are regarded as a critical hurdle in this issue. In the present review, we discuss the correlation of EBV antigens expression in the tumor cells and the induction of Tregs in tumor microenvironment. Treg subsets and its possible mechanism to attenuate the anti-tumor immunity in EBV associated malignancies are also discussed, following by the possible strategies of targeting Tregs in the future immunotherapy for EBV positive cancers.
 ...
PMID:Regulatory T cells and EBV associated malignancies. 1953 72